Bolt Biotherapeutics (NASDAQ:BOLT) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.39 and traded as low as $4.01. Bolt Biotherapeutics shares last traded at $4.12, with a volume of 43,870 shares changing hands.

Analyst Ratings Changes

BOLT has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, January 21st. Zacks Research lowered shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Performance

The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The stock has a 50-day moving average price of $5.51 and a 200-day moving average price of $5.39. The company has a market capitalization of $7.91 million, a price-to-earnings ratio of -0.18 and a beta of 0.95.

Institutional Investors Weigh In On Bolt Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after purchasing an additional 26,400 shares during the period. T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter valued at about $208,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Bolt Biotherapeutics in the fourth quarter valued at about $112,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth about $89,000. Finally, Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth about $85,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.